Targeting brain insulin signaling to combat metabolic disorders.

In this issue of Neuron, Li et al.1 show that follistatin-like 1 (FSTL1) emerges as a critical hypothalamic insulin sensitizer, whose pharmacological targeting attenuates body weight gain and improves systemic glucose metabolism, highlighting brain insulin signaling amplification as a promising strategy against obesity and associated metabolic disorders.